Closing
Do thiazolidinediones improve inflammation & biomarkers more than other treatments?
Mostly studied in type 2 & unspecified diabetes. Also asked versus placebo.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
A coin flip. So far, one result, not yet repeated.
NoUnsureYes
- Belief
- 0.50 (range 0.25–0.70)
- Trials for
- 1
- Trials against
- 0
- Inconclusive
- 1
Already under way
- Randomized, Parallel Group, Dose Escalation Trial of Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis…NCT06729996 · recruiting · started 2025
- Evaluation of Pioglitazone and Empagliflozin Combination Therapy in Type 2 Diabetes Patients With Metabolic Dysfunction-Associated Fatty Liver DiseaseNCT06989723 · recruiting · started 2025
- Pioneering and Affordable Strategies to Prevent Progression of Prediabetes, Obesity and CV Risk in HispanicsNCT06446531 · recruiting · started 2024
- A Multicenter, Prospective, Non-interventional Observation Study to Evaluate the Safety and Effectiveness of OAD Triple Therapy in Korean Type 2 Diabetic…NCT06838286 · recruiting · started 2024
- Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on…NCT02879409 · active not recruiting · started 2016
The evidence so far
- Registered trials
- 33
- With posted results
- 11
- Published papers
- 5
Of 8 decided analyses: 5 favor thiazolidinediones, 3 find no difference, 0 favor the comparator.
Papers
- Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.Trial report · 2006
- Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study.Trial report · 2012
- Fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment.Trial report · 2011
- Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects.Trial report · 2004
- Pioglitazone reduces monocyte activation in type 2 diabetes.Trial report · 2009
Trials
- A Phase 3b, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Pioglitazone HCl and Metformin HCl Fixed-Dose Combination Therapy Compared to Pioglitazone HCl Monotherapy and to Metformin HCl Monotherapy in the Treatment of Subjects With Type 2 DiabetesNCT00727857 · 6 posted results
- Effects of a Pioglitazone/Metformin Fixed Combination in Comparison to Metformin in Combination With Glimepiride on Diabetic DyslipidemiaNCT00770653 · 3 posted results
- Effect of Pioglitazone on Insulin Resistance, Progression of Atherosclerosis and Clinical Course of Coronary Heart DiseaseNCT03011775 · 1 posted result
- Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?NCT02879409
- A Long Term, Open Label, Randomised Study in Patients With Type 2 Diabetes, Comparing the Combination of Rosiglitazone and Either Metformin or Sulfonylurea With Metformin Plus Sulfonylurea on Cardiovascular Endpoints and GlycaemiaNCT00379769 · 3 posted results
- A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed Type 2 Diabetes MellitusNCT00279045
- EMPOWIR: Enhance the Metabolic Profile of Women With Insulin Resistance: Carbohydrate Modified Diet Alone and in Combination With Metformin or Metformin Plus Avandia in Non-diabetic Women With Midlife Weight Gain and Documented Insulin Elevations (Syndrome W)NCT00618072 · 3 posted results
- A 52 Week Randomized, Double-Blind, Multicenter, Mechanistic Study With a 24 Week Open-Label Follow-Up to Evaluate the Effect of AVANDIA TM on Bone in Postmenopausal Women With Type 2 Diabetes MellitusNCT00679939 · 14 posted results